The pathogenesis of nonalcoholic fatty liver disease (NAFLD) is complex. Vitamin D (VitD) has been implicated in NAFLD pathogenesis because it has roles in immune modulation, cell differentiation and proliferation, and regulation of infl ammation. We evaluated the association of VitD levels, hepatic gene expression for VitD metabolizing genes, and NAFLD histological severity.
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is becoming an increasingly prevalent form of chronic liver disease in the Western world. Recent epidemiologic studies report a prevalence of ~25-45% in the general population (1) (2) (3) . NAFLD is a clinicopathologic spectrum characterized by isolated hepatic steatosis or NAFL on the most benign end of the spectrum, to nonalcoholic steatohepatitis (NASH) characterized by fat with necroinfl ammation and ballooned hepatocytes with or without hepatic fi brosis, to cirrhosis on the severe end of the spectrum. NAFLD occurs in the absence of signifi cant alcohol use or viral hepatitis and is strongly associated with weight gain, decreased physical activity, and metabolic syndrome ( 1 ) . NASH carries elevated risk for progression to cirrhosis thus incurring an increased risk for hepatocellular carcinoma ( 4, 5 ) . Th e metabolic syndrome is considered a key factor in the pathogenesis of NAFLD, though the acquisition and progression of NAFLD is complex and currently incompletely understood ( 1 ) .
Vitamin D (VitD) defi ciency, characterized by low serum levels of 25-hydroxyvitamin D, is associated with obesity, sedentary lifestyles, and insulin resistance ( 6, 7 ) . Th us, a strong association between VitD defi ciency and NAFLD is plausible ( 8 ) . In vitro , VitD has been implicated in immune modulation, cell diff erentiation and proliferation, and regulation of infl ammation suggesting that VitD may be a target for therapeutic intervention in the treatment of NAFLD and NASH ( 8 ) . Indeed, recent studies have reported an association of VitD with features of chronic liver injury, particularly steatohepatitis and fi brosis, in adults and children (8) (9) (10) (11) (12) (13) . In vitro and in vivo preclinical studies have found that VitD decreases hepatic stellate cell activation, suggesting the potential for VitD to protect against or ameliorate hepatic fi brosis ( 14, 15 ) . VitD has also been shown to promote a Th 2 anti-infl ammatory response in lymphocytes, thereby supporting VitD supplementation as a potential anti-infl ammatory intervention for treatment of NASH ( 16 ) . However, other studies demonstrate a lack of association with VitD and NAFLD (17) (18) (19) .
Th e aims of our study were three-fold: (1) to investigate the relationship between VitD in age, gender and body mass index (BMI)-matched cohorts with and without biopsy-proven features of NAFLD; (2) to evaluate the association of VitD levels with histologic severity of NAFLD; and (3) to utilize hepatic gene expression to support or refute the clinical association of VitD with hepatic steatosis, lobular and portal infl ammation, ballooned hepatocytes, nonalcoholic steatohepatitis activity score (NAS), and fi brosis severity in NAFLD.
METHODS

Study cohort
We performed cross-sectional analyses using the Duke University Health System (DUHS) NAFLD Clinical Database and Biorepository. Th e DUHS NAFLD Clinical Database and Biorepository is a prospective, open-enrolling, and annotated clinical database of patients who underwent evaluation for the suspected diagnosis of NAFLD approved by the Institutional Review Board ( 20, 21 ) . Patients are enrolled either at time of standard of care percutaneous liver biopsy, or intraoperative liver biopsy during bariatric surgery. For our analysis, patients with 25-hydroxyvitamin D levels within 3 months of liver biopsy were included. Given the unknown impact of profound weight loss and the bariatric surgery intervention on serum VitD, only patients enrolled with a serum 25-hydroxyvitamin D level within 3 months prior to bariatric surgery were studied. Th e presence of NAFLD was defi ned histologically according to the criteria established by the NASH Clinical Research Network ( 4 ). Patients with no pathologic diagnosis for NAFLD (i.e., hepatic steatosis <5%, absence of necroinfl ammation, ballooned hepatocytes or hepatic fi brosis) nor any other type of chronic liver disease served as a control cohort in our analysis. Exclusion criteria included: (i) current alcohol consumption of ≥14 servings per week (for men) and ≥7 servings per week (for women), (ii) serological evidence of alternative forms of liver disease (e.g., chronic viral hepatitis, primarily biliary cirrhosis autoimmune hepatitis, hemochromatosis, Wilson's disease, alpha-1-antitrypsin defi ciency), or (iii) histological features suggesting co-existing liver diseases. All data was extracted via systematic chart review to include demographics, BMI, medical history, and concomitant medications at time of biopsy. Only patients with laboratory results for lipids, glycemic control, and creatinine within 3 months of liver biopsy, or prior to liver biopsy for those undergoing bariatric surgery, were included.
For our analysis, diabetes mellitus was defi ned as presence of an existing medical diagnosis in medical record, glycosylated hemoglobin (HbA1c) >6.5%, and/or use of any medication (oral insulin sensitizing agents or insulin therapy) used to treat diabetes mellitus. Hypercholesterolemia was defi ned as an existing diagnosis in the medical record, total cholesterol >200 mg/dl, and/or use of cholesterol-lowering medication. Hyperlipidemia was defi ned as an existing diagnosis in the medical record, low-density lipoprotein >110 mg/dl, triglycerides >200 mg/dl, and/or use of lipid-lowering therapy at the time of liver biopsy. Hypertriglyceridemia was defi ned as an existing diagnosis in medical record and/or isolated triglycerides >200 mg/dl. Hypertension was defi ned as an existing medical diagnosis and/or use of antihypertensive medication at time of liver biopsy. VitD supplementation included ergocalciferol, cholecalciferol, calcitriol, and/or any multivitamin use containing low-dose VitD at the time of liver biopsy. With the understanding that VitD levels may diff er based on skin pigmentation ( 22 ), we also considered the potential confounding variable for "light skin" as those subjects who are White or Asian and "dark skin" as those who are Black or Hispanic.
Assessment of serum 25-hydroxyvitamin D levels
Serum VitD levels were collected and measured at the DUHS clinical laboratory using the Liaison (DiaSorin; Saluggia, Italy) 25-OH VitD Total assay (direct competitive chemiluminescence immunoassay). Understanding that seasonal changes may aff ect VitD levels (our primary predictor), the time of year (high sunlight or low sunlight periods based on US seasonality data ( 23 )) was considered. VitD defi ciency was defi ned as a 25-hydroxyvitamin D level <20 ng/ml, insuffi ciency 20-30 ng/ml, and normal >30 ng/ml.
Liver histology
All liver biopsy specimens were stained with hematoxylin-eosin and Masson trichrome stains, and reviewed and scored according to the published NASH Clinical Research Network grading and scoring system ( 4 ). For our analysis, fi brosis stages 1a, 1b and 1c were combined and treated as stage 1. NASH was defi ned as a nonalcoholic steatohepatitis activity score (NAS)≥4 points. Portal infl ammation was evaluated as present (grade 1) or absent (grade 0). Th e grade of steatosis, infl ammation and ballooning, stage of fi brosis, and NAS were evaluated as primary outcomes.
Hepatic gene expression data for VitD metabolizing genes
Our group previously published results of hepatic gene expression in patients with mild (i.e., fi brosis stage 0-1; n =40) versus advanced (i.e., fi brosis stage 3-4, n =32) NAFLD in a subset of patients from the DUHS NAFLD Clinical Database and Biorepository ( 24 ) . We reanalyzed our gene expression data for candidate genes in the VitD metabolic pathway and downstream mediators of VitD signaling including: VitD receptor (VDR); VitD-binding protein,
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Vitamin D Not Associated With NAFLD Severity which in humans is encoded by the group specifi c component ( GC ) gene; VitD3 25-hydroxylase also known as Cytochrome P450, Family 27, Subfamily A, Polypeptide1 ( CYP27A1 ); VitD 25-hydroxylase which is encoded by the Cytochrome P450 2R1 ( CYP2R1 ) gene; Cytochrome P450 3A4 ( CYP3A4 ); 25-hydroxyvitamin D3 1-alpha-hydroxylase also known as Cytochrome P450 27B1 ( CYP27B1 ); 1,25-diydroxyvitamin D3 24-hydroxylase also known as Cytochrome P450 24A1 ( CYP24A1 ), parathyroid hormone ( PTH ), retinoic X receptor ( RXR ), nuclear receptor coactivator ( NCOA ), SMAD , and peroxisome proliferator-activated receptor ( PPAR ).
Statistical analysis
Clinical characteristics of NAFLD and the control group were summarized using standard descriptive statistics and compared using two-sided t -tests or Wilcoxon's rank-sum tests for continuous predictors and chi-squared tests or Fisher's exact tests for categorical variables. Signifi cance was defi ned as a P -value ≤0.05. Generalized linear models were used to associate the grade of steatosis, infl ammation and ballooning, NAS and hepatic fi brosis (primary outcomes) with 25-hydroxyvitamin D level (primary predictor). Age, gender, race, time of year of VitD level acquisition, presence of VitD supplementation, BMI, renal function, and HbA1c, as well as diabetes mellitus, hypertension, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia diagnosis status were considered as potential confounders and included in the model. Generalized linear models were used to assess gene associations with primary outcomes while controlling for age, gender, BMI, race, diabetes mellitus, hyperlipidemia, hypertension, hypercholesterolemia, hypertriglyceridemia and HbA1c ( P <0.05 considered signifi cant). Th e Benjamini-Hochberg procedure was used to correct for multiple testing with false discovery rate at 5%. All statistical analyses were performed using MatLab (MathWorks; Natick, MA).
RESULTS
Patient characteristics
Clinical characteristics of our study cohort ( n =283; 2 Asian, 227 White, 45 Black, 9 Other/Hispanic) are summarized in Table 1 . All subjects were from same geographic region equidistant from the equator (34°N to 37°N latitude). NAFLD ( n =244), as compared with control patients ( n =39), were more likely to have higher HbA1c (6.5±1.2 vs. 5.9±1.0; P =0.009) and light skin (83.6% vs. 64.1%, P =0.005). Patients enrolled from the Metabolic and Weight Loss Surgical Program were less likely to have biopsyproven NAFLD ( P =0.008). Notably, no diff erence in 25-hydroxyvitamin D level was observed in NAFLD patients versus controls (27.6±11.8 ng/ml vs. 27.9±12.8 ng/ml; P =0.88; Figure 1 ). Categorizing by normal, insuffi cient, and defi cient according to NAFLD vs. controls demonstrated that the diagnosis of NAFLD did not infl uence the proportions of these categories when compared with controls ( P =0.29).
VitD levels did not vary between high vs low sunlight specimen collection periods (28.3±11.3 vs. 26.8±12.6, P =0.28). VitD levels were signifi cantly diff erent across the BMI spectrum for overweight (BMI 25-29.9), obese (BMI 30-39.9), or extremely obese (BMI>40) individuals (32.7±11.9, 28.2±12.3, 23.5±9.6, P =0.0007), notably dropping with increased BMI. VitD levels were higher in patients on supplementary VitD ( n =93; 31.2±13.0 vs. 25.9±10.9, P =0.0003) and in those with light skin (28.4±11.6 vs. 24.6±12.8, P =0.039).
VitD and histological features of NAFLD
Th e relationship between 25-hydroxyvitamin D level and histological features of NAFLD are summarized in Table 2 . Individual patient box-plot data as categorized across histologic features by grade and stage is depicted in Figure 2 . Data depict results of adjusted multivariable regression models. No association was found between 25-hydroxyvitamin D level and histological grade of hepatic steatosis, lobular infl ammation, portal infl ammation, hepatocellular ballooning, or NAS. VitD level increased with increasing fi brosis stage 0 to 3 (stage 0 ( n =39); stage 1 ( n =78); 
VitD hepatic gene expression profi le analysis
Details of the hepatic gene expression analysis as it pertains to VitD metabolism with primary outcomes (grade of steatosis, infl ammation and ballooned hepatocytes, NAS and fi brosis stage) are reported in Supplementary Tables 1 and 2 . NCOA7 , PTH1R , RXRA , SMAD9 , and SMAD2 were noted to be diff erentially expressed with an unadjusted raw p-value ( P <0.05) when comparing mild (stage 0-1 fi brosis) and advanced (stage 3-4 fi brosis) NAFLD, though these fi ndings did not persist aft er multiple corrections and adjusting for confounders ( Table 3 ) . One of the three gene probes relating to NCOA7 was diff erentially expressed in livers with mild vs. advanced fi brosis aft er multiple corrections and adjusting for confounders ( P =0.005). One of the nine gene probes relating to PPARA was diff erentially expressed according to the severity of hepatocyte ballooning ( P <0.05); however, this association did not persist aft er adjusting for multiple comparisons and confounders. One of the fi ve gene probes relating to CYP3A4 was diff erentially expressed in livers with higher NAS scores ( P <0.05); however, this association did not persist aft er correcting for multiple comparisons and adjusting for confounders. No diff erences in any genes involved in VitD metabolism ( CYP24A1 , CYP27 ,
, or SMAD7 ) were associated with steatosis, lobular infl ammation, ballooned hepatocyte grades, NAS scores, or fi brosis stage. 
DISCUSSION
To our knowledge, this is the fi rst study that has investigated the relationship between NAFLD severity, serum 25-hydroxyvitamin D levels, and hepatic expression of VitD metabolizing genes. Importantly, our study also included a control group that did not have NAFLD on liver biopsy but which was otherwise similar to the NAFLD cohort with regards to age, gender, BMI, and use of VitD supplements ( 4 ). We were unable to demonstrate that levels of serum 25-hydroxyvitamin D levels diff ered between NAFLD patients and controls without NAFLD. Similarly, we found no associations between VitD levels and liver histology among the NAFLD patients. Hepatic expression of multiple genes involved in VitD metabolism was also unrelated to diff erences in NAFLD severity. Th us, we did not fi nd an association between VitD and NAFLD diagnosis or histological severity in our cross-sectional analysis of biopsy-proven NAFLD patients. Patel et al.
Th e presence of a non-NAFLD control group with comparable BMI, age and gender, and VitD supplement use, is powerful because this removes confounders that might infl uence both VitD levels and NAFLD susceptibility ( 6, 7 ) and allows us to evaluate whether or not VitD levels directly associate with liver injury. Indeed, the lack of a diff erence in VitD defi ciency between controls and NAFLD in this study may refl ect the lack of diff erence in risk factors for VitD defi ciency in our control vs. NAFLD cohort. Consistent with this concept, Nelson et al. ( 13 ) demonstrated that VitD defi ciency prevalence increases with obesity and diabetes mellitus and both the control and NAFLD groups in our study were enriched with obese, diabetic patients.
We were also careful to search for other factors that might infl uence VitD levels and found that light skin was more prevalent in the patients with NAFLD than controls (83.6% vs. 64.1%, P =0.005). Skin pigmentation is an important variable in discriminating VitD levels as photochemical production from the skin is an important source of VitD production ( 26 ) . As such, light-skinned individuals more effi ciently process VitD from sun exposure as compared with dark-skinned individuals ( 22 ) . Furthermore, VitD level varies seasonally due to sunlight exposure ( 23 ) . Th erefore, when developing our multivariate regression model we controlled for skin pigmentation and month of specimen collection for VitD blood levels grouped by high and low sunlight months per US seasonal data ( 23 ) . Our multivariate regression model showed no association of VitD level with histologic severity in NAFLD, fi ndings consistent with recent histology-based studies (17) (18) (19) .
When evaluating the controversy regarding VitD and NAFLD, it is important to note that many of the studies that have suggested a relationship between VitD defi ciency and NAFLD lacked wellmatched controls and/or relied on liver ultrasounds for diagnosis of NAFLD (27) (28) (29) (30) (31) (32) . Studies which reported a correlation between histological severity of NAFLD and VitD defi ciency were oft en limited by small samples sizes ( n <65 patients) ( 9, 11, 31, 33 ) . Th e largest study to demonstrate low VitD concentration as an independent predictor of histological severity of NAFLD included 148 patients and 39 control patients that were signifi cantly dissimilar in regards to age and BMI ( 12 ) . Very recently, Nelson et al. ( 13 ) evaluated 190 adults with biopsy-proven NAFLD and noted VitD deficiency was present in 55% and was independently associated with NASH and histological severity. However, it is notable that potential confounders for VitD defi ciency, such as BMI, obesity, diabetes mellitus, and metabolic syndrome were relatively enriched in the VitD-defi cient NAFLD group versus the VitD-suffi cient NAFLD group ( 13 ) . In the current study, we evaluated 244 patients with biopsy-proven NAFLD and 39 well-matched controls without NAFLD on liver biopsy and our fi ndings are consistent with other investigators who have reported no association between VitD and the histological features of NAFLD (17) (18) (19) . Specifi cally, Bril et al. ( 17 ) reported no diff erences in VitD status of patients with defi nite NASH ( N =127) and patients without NASH ( N =58) aft er controlling for age, diabetes mellitus, and total adiposity. Th us, the two largest, well-controlled studies of VitD and human NAFLD have concordant results with neither study demonstrating a relationship between VitD defi ciency and NAFLD severity.
Our study is the fi rst to utilize hepatic gene expression to confi rm or refute the results of a cross-sectional case-control analysis attempting to defi ne the association of VitD with NAFLD severity. Th e three main steps in VitD metabolism (25-hydroxylation, 1α -hydroxylation, and 24-hydroxylation) are performed by cytochrome P450 complexes. Th e liver has been established as the primary (if not the only) location of 25-hydroxylation of VitD, which is primarily due to CYP2R1 activity ( 34 ) . CYP2R1 , and other key complexes such as CYP27B1 (major 1-hydroxylase) and CYP24A1 (major 24-hydroxylase), were not found to be diff erentially expressed based on NAFLD fi brosis severity. Furthermore, our fi ndings did not show a signifi cant diff erence in VDR (the transcription factor that mediates 1,25(OH) 2 D activity) expression or its primary heterodimer partner RXR ( 34 ) . In contrast, Barchetta et al . reported that expression of hepatic VDR as assessed by immunohistochemistry decreased as steatosis severity, lobular infl ammation, and NAFLD score increased ( 33 ) . Th e decreased expression of hepatic VDR assessed by immunohistochemistry was independent of BMI or insulin resistance ( 33 ) .
GC gene expression is predominately active in hepatocytes and codes for VitD-binding protein, the main carrier protein for VitD ( 35 ) . VitD levels have been shown to be infl uenced by GC gene polymorphisms, and the rs222054 SNP has been identifi ed through a genome-wide association study to be associated with NAFLD ( 36, 37 ) . Our study did not show a diff erence in GC gene expression across fi brosis stage in NAFLD patients. Furthermore, genes that encode for downstream mediators of the VitD pathway (i.e., SMAD , NCOA , and PPAR ) were also not diff erently expressed in mild versus advanced NAFLD, with one caveat. We did note that one of the three gene probes relating to NCOA7 remained diff erentially expressed in NAFLD livers stratifi ed by fi brosis stage aft er adjusting for confounders and multiple comparisons. We did not consider this signifi cant in our interpretation of the data as a difference in the expression of a splice variant, cross-hybridization with other genes which belong to a highly similar gene family, or diff erences in design quality of the probes may explain the association with only one probe for the NCOA7 gene. Th e relationship of NCOA7 with NAFLD severity would have been more convincing had a signifi cant association with all three gene probes for NCOA7 been noted. Furthermore, the lack of diff erential expression VDR , GC , and CYP complexes in mild vs. advanced NAFLD is consistent with the lack of an association between serum VitD levels and NAFLD severity in this study and thus, the aggregate data support the conclusion that there is no signifi cant relationship between VitD defi ciency and histological severity of NAFLD.
Our study has several strengths. Th e conclusions are based on the analysis of a large number of patients with biopsy-proven NAFLD in whom a standardized approach was used to grade and stage the individual histologic components of NAFLD. Th e study also included a control cohort that did not have NAFLD on liver biopsy but was enriched with metabolic risk factors for NAFLD and VitD defi ciency and this allowed us to more accurately discern the association of VitD with NAFLD. Other potential confounders such as skin pigment (categorized by race) and presence of VitD supplementation were also considered in our analysis. Controlling for underlying renal function was also considered and was found not to signifi cantly change results. Finally, our study is the fi rst to evaluate the relationship between hepatic expression of several VitD metabolizing genes, including CYP24A1 , CYP27 , CYP2R1 , CYP3A4 , GC , and VDR , and NAFLD severity. No relationship was demonstrated between expression of these genes and NAFLD severity, supporting the clinical fi ndings which demonstrated a lack of association between histologic features of NAFLD and VitD levels. Although fi ve other VitD-related genes ( NCOA7 , PTH1R , SMAD2 , SMAD9 , and RXRA ) were signifi cantly diff erentially expressed in livers with mild vs. advanced NAFLD, these associations did not persist aft er controlling for confounding factors and multiple comparisons, further supporting the lack of an association between VitD defi ciency and NAFLD severity.
Our study has a few limitations. Th e cross-sectional analysis and retrospective study design did not allow us to defi ne the duration or type of VitD supplementation. Another limitation is that VitD levels were not always obtained on the same day as the liver biopsy. To minimize the eff ect of displacement of the VitD level (primary predictor) from liver histology (primary outcome), only patients with VitD levels within 3 months of liver biopsy were included in the study. Th e additional consideration of seasonal eff ects further minimizes this concern. Further, seasonal eff ect on VitD would not otherwise be anticipated to fl uctuate signifi cantly within a timeframe of 3 months. A cross-sectional analysis limits the ability to discern cause-eff ect relationships between VitD and NAFLD, and does not allow us to evaluate the impact of VitD status over time. Lastly, our analysis is limited by the lack of data regarding serum calcium, phosphorus, parathyroid hormone, and bone mineral density as such variables are not routinely checked in the context of standard clinical care for the majority of patients with NAFLD.
In summary, this study demonstrates no relationship between VitD defi ciency and the presence or histological severity of NAFLD. Although prior pre-clinical studies provide evidence that implicate VitD in NAFLD pathogenesis, our study suggests that VitD deficiency is not associated with NAFLD severity in patients. Although we provide several lines of evidence which refute the hypothesis that VitD defi ciency promotes human NAFLD, and our results are consistent with those that have been reported by some other groups, they are not in agreement with some other human data. Th us, the role of VitD in NAFLD pathogenesis in humans warrants further study.
